Glibenclamide in Aneurysmatic Subarachnoid Hemorrhage

• Status: Unknown status
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

A randomized, double-blind and prospective trial meant to evaluate the use of Glibenclamide on acute aneurysmatic subarachnoid hemorrhage. Patients will allocated randomly in two groups, one for 05 mg daily intake of glibenclamide for 21 days and another for control with placebo. General clinical data and late cognitive status will be accessed in both groups.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Sao Paulo General Hospital
• Treatments: Glyburide

Criteria

Inclusion Criteria:

• Radiological confirmatory evidence of an aneurysmal subarachnoid hemorrhage (by digital subtraction angiography, CT angiography, or magnetic resonance angiography)

• Presentation less than 96 h from ictus

Exclusion Criteria:

• Patients taking glibenclamide therapy at presentation

• Pregnancy

• Hunt & Hess V

• Known renal or hepatic impairment

• Patient not fully independent before bleed,

• Strong suspicion of drug or alcohol misuse

• Patient taking warfarin-type drugs

• Suspected additional life-threatening disease